头孢他啶-阿维巴坦耐药肺炎克雷伯菌的分子分析
该研究对意大利罗马六家医院31例患者的KPC产酶肺炎克雷伯菌临床分离株(共39株)进行分子分析,发现26/31患者携带blaKPC突变株,涉及11种不同突变(含4种新突变),且14/31病例对头孢他啶-阿维巴坦和碳青霉烯类均耐药。
要点
- 头孢他啶-阿维巴坦耐药KPC产酶肺炎克雷伯菌多携带blaKPC突变,涉及单氨基酸替换、插入或缺失。
- 高风险克隆ST512、101和307在罗马六家医院传播。
- 14/31病例对头孢他啶-阿维巴坦和碳青霉烯类双重耐药,需警惕多重耐药表型选择。
核心结论
- 在26/31头孢他啶-阿维巴坦耐药KPC产酶肺炎克雷伯菌中检出blaKPC基因突变,包括单氨基酸替换、插入或缺失。
- 14/31病例分离株对头孢他啶-阿维巴坦和碳青霉烯类均耐药,提示可能筛选出多重耐药表型。
研究设计与样本
- 研究为1年调查,收集意大利罗马六家医院31例患者的KPC产酶肺炎克雷伯菌临床分离株,共39株(其中8例有治疗前额外菌株)。
- 采用自动化系统、肉汤微量稀释法和E-test测定抗菌药物敏感性,全基因组测序分析获得性耐药基因,MLST和cgMLST进行分子分型,Sanger测序分析blaKPC基因突变,并探究OmpK35和OmpK36外膜蛋白可能的突变。
主要发现
- 分子分析揭示ST512、101和307高风险克隆的流行。
- 26/31患者携带突变KPC变异体,5例为野生型KPC-3。
- 检测到的KPC变异体中,blaKPC-3基因内有11种不同突变,其中4种为新突变。
临床怎么用
- 对头孢他啶-阿维巴坦耐药的KPC产酶肺炎克雷伯菌感染,应进行blaKPC基因测序以识别突变。
- 关注高风险克隆(ST512、101、307)的传播,加强医院感染防控。
- 对头孢他啶-阿维巴坦和碳青霉烯类双重耐药菌株需警惕多重耐药表型的出现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To analyse the strains collected during a 1-year survey of ceftazidime-avibactam-resistant KPC-producing Klebsiella pneumoniae, in order to investigate the molecular mechanisms potentially responsible for their resistant phenotype. METHODS: Clinical KPC-producing K. pneumoniae isolates were collected from 31 patients in six different hospitals in Rome. For eight of the patients, an additional strain grown before the start of treatment was also available, bringing the total of isolates studied to 39. Antimicrobial susceptibility was determined by automated system, broth microdiluition and E-test as appropriate. In silico analysis of acquired resistance genes was achieved by whole-genome sequencing, while multilocus sequence typing and core genome multilocus sequence typing were employed for molecular typing. Mutations associated with ceftazidime-avibactam resistance were identified by Sanger sequencing of the blaKPC gene. Possible mutations in OmpK35 and OmpK36 outer membrane proteins were also investigated. RESULTS: Molecular analyses highlighted the circulation of the ST512, 101 and 307 high-risk clones; 26 of the 31 patients carried a mutated KPC variant, five had a wild-type KPC-3. Among the KPC variants detected, 11 were different mutations within the blaKPC-3 gene, four of which were novel mutational changes. CONCLUSIONS: Different mutations including single amino-acid substitutions, insertions or deletions within the blaKPC gene were found in 26/31 ceftazidime-avibactam-resistant KPC-producing K. pneumoniae strains belonging to high-risk clones circulating in Italy. Of note, in 14/31 cases the isolates displayed resistance to both ceftazidime-avibactam and carbapenems, raising concerns for the possible selection of a multidrug-resistant phenotype.
引用
- Venditti C, Butera O, Meledandri M, et al. Molecular analysis of clinical isolates of ceftazidime-avibactam-resistant Klebsiella pneumoniae. Clin Microbiol Infect. 2021. PMID: 33775814. doi:10.1016/j.cmi.2021.03.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。